# AAPG catalysts: ASCENTAGE PHARMA GROUP INTERNATIONAL PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/aapg/catalysts

> ASCENTAGE PHARMA GROUP INTERNATIONAL (AAPG) has 16 upcoming catalysts. The next is the APG2575 primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: month only, quarter only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | ASCENTAGE PHARMA GROUP INTERNATIONAL |
| Ticker | AAPG (Nasdaq) |
| SEC CIK | 2023311 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/aapg |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| Feb 2024 | [Olverembatinib trial start](https://sec-api.dev/pdufa/olverembatinib) | AAPG |  | completed | "After receiving clearance from the FDA in February 2024 , we commenced enrollment in a registrational Phase III clinical trial of olverembatinib for previously treated CML - CP patients, both with and without T 315 I mutation (POLARIS - 2 ) ." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/2023311/000121390025032670/ea0238587ex99-1_ascentage.htm)) |
| May 2026 | [APG-115 primary completion](https://sec-api.dev/pdufa/apg-115) | AAPG | T-Prolymphocytic Leukemia; Non-Hodgkins Lymphoma | delayed | "NCT04496349 (A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-05-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04496349)) |
| December 2026 | [APG2575 primary completion](https://sec-api.dev/pdufa/apg2575) | AAPG | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT05147467 (Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05147467)) |
| Dec 2026 to Mar 2027 | [APG2575 topline data readout](https://sec-api.dev/pdufa/apg2575) | AAPG | Chronic Lymphocytic Leukemia; Small Lymphocytic Lymphoma | scheduled | "NCT05147467 (Study of APG-2575 in Patients With Relapsed/Refractory CLL/SLL): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05147467)) |
| Dec 2026 to Mar 2027 | [Lisaftoclax +btk inhibitor topline data readout](https://sec-api.dev/pdufa/lisaftoclax-btk-inhibitor) | AAPG | CLL/SLL | scheduled | "NCT06104566 (Global Trial in APG2575 for Patients With CLL/SLL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104566)) |
| December 2026 | [Lisaftoclax +btk inhibitor primary completion](https://sec-api.dev/pdufa/lisaftoclax-btk-inhibitor) | AAPG | CLL/SLL | scheduled | "NCT06104566 (Global Trial in APG2575 for Patients With CLL/SLL): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2026-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06104566)) |
| Mar to Jun 2027 | [Olverembatinib topline data readout](https://sec-api.dev/pdufa/olverembatinib) | AAPG | GIST | scheduled | "NCT06640361 (A Study of Olverembatinib in SDH-deficient GIST.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06640361)) |
| March 2027 | [Olverembatinib primary completion](https://sec-api.dev/pdufa/olverembatinib) | AAPG | GIST | scheduled | "NCT06640361 (A Study of Olverembatinib in SDH-deficient GIST.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-03-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06640361)) |
| Jun to Sep 2027 | [Olverembatinib topline data readout](https://sec-api.dev/pdufa/olverembatinib) | AAPG | Chronic Myeloid Leukemia; CML; CML, Chronic Phase | scheduled | "NCT06423911 (Study of Olverembatinib (HQP1351) in Patients With CML-CP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06423911)) |
| June 2027 | [Olverembatinib primary completion](https://sec-api.dev/pdufa/olverembatinib) | AAPG | Chronic Myeloid Leukemia; CML; CML, Chronic Phase | scheduled | "NCT06423911 (Study of Olverembatinib (HQP1351) in Patients With CML-CP): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-06-30 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06423911)) |
| August 2027 | [Lisaftoclax (apg-2575) primary completion](https://sec-api.dev/pdufa/lisaftoclax-apg-2575) | AAPG | CLL/SLL | scheduled | "NCT06319456 (A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06319456)) |
| Aug to Nov 2027 | [Lisaftoclax (apg-2575) topline data readout](https://sec-api.dev/pdufa/lisaftoclax-apg-2575) | AAPG | CLL/SLL | scheduled | "NCT06319456 (A Study of Lisaftoclax (APG-2575) Combined With Acalabrutinib Versus Immunochemotherapy for Newly Diagnosed CLL/SLL.): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-08 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06319456)) |
| Dec 2027 to Mar 2028 | [Olverembatinib topline data readout](https://sec-api.dev/pdufa/olverembatinib) | AAPG | Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | scheduled | "NCT06051409 (A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06051409)) |
| December 2027 | [Olverembatinib primary completion](https://sec-api.dev/pdufa/olverembatinib) | AAPG | Ph+ ALL; Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | scheduled | "NCT06051409 (A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ ALL (POLARIS-1)): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2027-12-31 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06051409)) |
| May to Aug 2028 | [Apg-2575(lisaftoclax ) topline data readout](https://sec-api.dev/pdufa/apg-2575-lisaftoclax) | AAPG | Acute Myeloid Leukemia | scheduled | "NCT06389292 (A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-25 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389292)) |
| May 2028 | [Apg-2575(lisaftoclax ) primary completion](https://sec-api.dev/pdufa/apg-2575-lisaftoclax) | AAPG | Acute Myeloid Leukemia | scheduled | "NCT06389292 (A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2028-05-25 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06389292)) |
| June 2029 | [Lisaftoclax (apg-2575) primary completion](https://sec-api.dev/pdufa/lisaftoclax-apg-2575) | AAPG | Higher-risk Myelodysplastic Syndrome | scheduled | "NCT06641414 (Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641414)) |
| Jun to Sep 2029 | [Lisaftoclax (apg-2575) topline data readout](https://sec-api.dev/pdufa/lisaftoclax-apg-2575) | AAPG | Higher-risk Myelodysplastic Syndrome | scheduled | "NCT06641414 (Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).): Overall Status RECRUITING; Phase PHASE3; Primary Completion 2029-06 (ESTIMATED); Lead Sponsor Ascentage Pharma Group Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06641414)) |

## Drugs

- [APG-115](https://sec-api.dev/pdufa/apg-115): T-Prolymphocytic Leukemia
- [Apg-2575(lisaftoclax )](https://sec-api.dev/pdufa/apg-2575-lisaftoclax): Acute Myeloid Leukemia
- [APG2575](https://sec-api.dev/pdufa/apg2575): Chronic Lymphocytic Leukemia
- [Lisaftoclax (apg-2575)](https://sec-api.dev/pdufa/lisaftoclax-apg-2575): Higher-risk Myelodysplastic Syndrome, CLL/SLL
- [Lisaftoclax +btk inhibitor](https://sec-api.dev/pdufa/lisaftoclax-btk-inhibitor): CLL/SLL
- [Olverembatinib](https://sec-api.dev/pdufa/olverembatinib): GIST, Ph+ ALL, Chronic Myeloid Leukemia

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/aapg/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "AAPG catalysts: ASCENTAGE PHARMA GROUP INTERNATIONAL PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/aapg/catalysts

```bibtex
@misc{secapidev_companies_aapg_catalysts_20261116,
  title        = {AAPG catalysts: ASCENTAGE PHARMA GROUP INTERNATIONAL PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/aapg/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_aapg_catalysts_20261116","title":"AAPG catalysts: ASCENTAGE PHARMA GROUP INTERNATIONAL PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/aapg/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
